Welcome to our dedicated page for Bio-Key Intl news (Ticker: BKYI), a resource for investors and traders seeking the latest updates and insights on Bio-Key Intl stock.
BIO-key International, Inc. reports developments in identity and access management software, biometric authentication technology, and related security hardware. The company’s updates center on cloud-hosted and on-premise PortalGuard IAM, biometric-centric multi-factor authentication, Passkey:YOU, and devices such as Pocket 10 Finger Scanners and Mobile POS Pro. Customer news includes software license renewals, public-sector channel partnerships, defense deployments, and retail-bank biometric identification programs.
Financial and corporate updates also cover operating results, revenue contributions from services, license fees, and hardware, Nasdaq listing compliance, periodic-report timing, and share-structure actions such as the company’s 1-for-10 reverse stock split.
BIO-key (OTC: BKYI) reported Q1 2026 revenue of $2.15M, up about 34% year over year, with an 82% gross margin. Net loss narrowed to $165K. The company expects Q2 revenue of roughly $2.8M (about 65% above prior-year Q2) and 1H 2026 revenue of about $5M, up 50%, with anticipated first-half profitability and cash roughly in line with current levels. Current cash is $2.2M and stockholders’ equity is $7.43M. BIO-key highlighted finance, defense and government wins, but noted its shares were suspended from Nasdaq and now trade on OTC Markets as BKYI while it seeks relisting.
BIO-key (Nasdaq: BKYI) will have its common stock trading suspended from Nasdaq after the May 12, 2026 close and expects quotation on OTC Markets under BKYI starting May 13. The suspension reflects bid-price non-compliance and a delayed 2025 Form 10-K filing.
The company plans to seek a Nasdaq hearing and targets 1H 2026 revenue of $5M (up from $3.3M in 1H 2025) and profitability.
BIO-key (NASDAQ: BKYI) will host its Q1’26 investor call and webcast on Monday, May 18th at 10 a.m. ET. Chairman & CEO Mike DePasquale and CFO Cecilia Welch will lead the presentation and Q&A.
The event includes phone dial-in, live webcast, and a three-month replay.
BIO-key (Nasdaq: BKYI) announced a 1-for-10 reverse stock split effective with the opening of trading on April 30, 2026. The company had ~10.9 million shares outstanding as of April 28, 2026; post-split it will have ~1.1 million shares outstanding.
The Board approved the ratio after stockholder approval to assist BIO-key in regaining compliance with the Nasdaq minimum bid price requirement. According to the company, management is executing growth goals that include achieving profitability in the first half of 2026.
BIO-key (Nasdaq: BKYI) received a Notice of Non-Compliance from Nasdaq for failing to timely file its Annual Report on Form 10-K for the year ended December 31, 2025 under Nasdaq Rule 5250(c)(1).
The notice does not immediately affect listing or trading. The company is working with auditors and expects to file the Form 10-K next week.
BIO-key (Nasdaq: BKYI) expects 1H 2026 revenue of approximately $5.0M, up ~50% from $3.3M in 1H 2025, driven by software license momentum and stronger hardware sales.
The company expects positive net income in 1H 2026 versus a $1.9M loss in 1H 2025, a stable cash balance near $2.7M, and specific wins including a $1.04M one-year software renewal and over $1M in hardware contracts.
BIO-key (Nasdaq: BKYI) reported 2025 revenue of $6.1M, preliminary Q1’26 revenue of $2.2M (up 37% vs Q1’25), and year-end cash of $2.7M. BIO-key cited defense, financial, and international partner traction, hardware growth, reduced SG&A, and an expectation of stronger 2026 results while noting the 2025 audit is not yet complete.
BIO-key (NASDAQ: BKYI) will host its 2025 year-end investor call on Tuesday, March 31, 2026 at 10:00 a.m. ET, with results released prior to market open. The call will be led by Mike DePasquale, Chairman & CEO, and Cecilia Welch, CFO, and will include a Q&A session.
Dial-in numbers, webcast/replay availability for three months, and audio replay details are provided for investors.
BIO-key (NASDAQ: BKYI) announced a strategic partnership with TD SYNNEX Public Sector (DLT) on March 12, 2026 to deliver identity-bound biometric and IAM solutions to U.S. federal, state, and local agencies. The collaboration integrates PortalGuard and Passkey:YOU into DLT contract vehicles to simplify procurement and support Zero Trust, phishing-resistant MFA, and compliance with CJIS, HIPAA, and NIST SP 800-171.
Key capabilities include NIST-tested, FBI-certified fingerprint biometrics, centralized SSO/IDaaS via PortalGuard, multi-factor authentication across 20+ methods, and self-service tools to reduce help-desk costs.
BIO-key (NASDAQ: BKYI) reported a new $280,000 order from a foreign defense ministry, bringing that customer's bookings to $1.14M in the past 12 months and BIO-key's total military/defense orders to over $2M in the last year.
The company highlights demand for phoneless, tokenless biometric authentication for SCIF and FME environments, support for more than 50,000 licensed users at the customer, and certifications including NIST, FBI FAP and FIPS 201.